• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injection Regimens in Children and Young People at Diagnosis of Type 1 Diabetes

byKyle HoffmanandAliya Ramjaun
April 13, 2019
in Chronic Disease, Endocrinology, Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) are two forms of intensive insulin regimens utilized by patients with type 1 diabetes. Here, MDI and CSII are compared in terms of their safety, efficacy, and cost in the first year after a diagnosis of type 1 diabetes. This randomized controlled trial and economic evaluation enrolled 294 patients across multiple centers in England and Wales. Patients with a new diagnosis of type 1 diabetes between the ages of 7 months and 15 years were randomized to receive either MDI or CSII within 14 days of diagnosis. Titration occurred according to local clinical practice. Researchers found that glycated hemoglobin (HbA1c) at 1 year was not significantly different between the CSII and MDI arms (mean difference 2.4 mmol/mol, 95% CI -0.4 to 5.3, p=0.09). Additionally, there was no significant difference in the proportion of patients achieving a HbA1c less than 58 mmol/mol. Parents reported an improvement in quality of life scores with CSII, as compared to MDI, however, children did not. Additionally, CSII was more expensive by $2,474 per year (95% CI $2,116 to $2,792) and was not associated with a significant difference in incremental cost per quality adjusted life year (difference -0.006, 95% CI -0.031 to 0.018). Investigators therefore concluded that there was no glycemic control benefit to CSII, as compared to MDI, in the first year after a diagnosis of type 1 diabetes, despite it being more expensive.

Click to read the study in BMJ

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes

#VisualAbstract: Automated Insulin Delivery Effectively Reduces Blood Glucose Levels in Type 2 Diabetes

Weekly insulin efsitora noninferior to daily degludec in reducing glycated hemoglobin levels

Tags: continuous subcutaneous insulin infusion (CSII)hba1cinsulinType 1 Diabetes Mellitus
Previous Post

HCV-positive heart and lung transplant likely safe with post-transplant sofosbuvir-velatasivir treatment

Next Post

Quick Take: Effectiveness of a Brief Group Psychological Intervention for Women in a Post-Conflict Setting in Pakistan

RelatedReports

Compliance-linked incentives increase infant immunizations rates in rural India
Endocrinology

Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes

June 16, 2025
#VisualAbstract: Automated Insulin Delivery Effectively Reduces Blood Glucose Levels in Type 2 Diabetes
StudyGraphics

#VisualAbstract: Automated Insulin Delivery Effectively Reduces Blood Glucose Levels in Type 2 Diabetes

March 31, 2025
Insulin costs rose exponentially, regardless of formulation or patent
Cardiology

Weekly insulin efsitora noninferior to daily degludec in reducing glycated hemoglobin levels

March 3, 2025
#VisualAbstract: Oral Glucose-Lowering Agents are Not Noninferior to Insulin for Gestational Diabetes
StudyGraphics

#VisualAbstract: Oral Glucose-Lowering Agents are Not Noninferior to Insulin for Gestational Diabetes

January 20, 2025
Next Post
Earlier puberty associated with increased risk of depression in girls

Quick Take: Effectiveness of a Brief Group Psychological Intervention for Women in a Post-Conflict Setting in Pakistan

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Quick Take: Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation System

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.